Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Baudax Bio Inc BXRXQ

Healthcare
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in... see more

Recent & Breaking News (PINL:BXRXQ)

Baudax Bio Announces $17.6 Million Offering Priced At-the-Market under Nasdaq Rules

GlobeNewswire February 8, 2021

Baudax Bio Announces Exercise of Warrants for Gross Proceeds of $13.4 Million

GlobeNewswire January 21, 2021

Baudax Bio to Present at the H.C. Wainwright BioConnect 2021 Conference

GlobeNewswire January 6, 2021

Baudax Bio Announces $12 Million Offering Priced at a Premium to Market

GlobeNewswire December 17, 2020

Baudax Bio to Participate in the Piper Sandler 32nd Annual Healthcare Conference

GlobeNewswire November 30, 2020

Baudax Bio Announces $12 Million Offering Priced at a Premium to Market

GlobeNewswire November 23, 2020

Baudax Bio Announces Publication of ANJESO® Network Meta-Analysis in the Peer-Reviewed Journal BMC Anesthesiology

GlobeNewswire November 20, 2020

Baudax Bio Announces an additional Orange Book listed patent for ANJESO®

GlobeNewswire November 19, 2020

Baudax Bio Reports Third Quarter 2020 Financial Results

GlobeNewswire November 9, 2020

Baudax Bio to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020

GlobeNewswire November 2, 2020

Baudax Bio Provides Commercial and Corporate Update

GlobeNewswire October 20, 2020

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 2, 2020

Baudax Bio to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

GlobeNewswire September 18, 2020

Baudax Bio Awarded Group Purchasing Agreement with Premier Inc. for ANJESO®

GlobeNewswire August 25, 2020

Baudax Bio Appoints Arnold Baskies, M.D. and Andrew Drechsler to Board of Directors

GlobeNewswire August 20, 2020

Baudax Bio Reports Second Quarter 2020 Financial Results

GlobeNewswire August 10, 2020

Baudax Bio to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020

GlobeNewswire August 6, 2020

Baudax Bio Secures Permanent J-Code (J1738) for ANJESO® from Centers for Medicare and Medicaid Services

GlobeNewswire August 6, 2020

Baudax Bio Announces Presentation of New Phase IIIb ANJESO® Data at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Meeting

GlobeNewswire July 30, 2020

Baudax Bio Secures Pharmacy Supplier Agreement with Vizient Inc. for ANJESO®

GlobeNewswire July 20, 2020